Slayback Pharma focuses on complex generics and specialty pharmaceutical products, supported by an R&D team in India and operations in the U.S., India and Europe. Since its inception in 2011, the company has achieved multiple sole first-to-file ANDAs, 505(b)(2) filings, approvals and launches. Recent commercial successes include the Hydroxyprogesterone 5 ml vial generic ANDA—the first generic ANDA approved and launched in the U.S.—for which Slayback holds the largest market share, and prior launches such as Propofol Injectable Emulsion. The company employs a team of 85 people. Slayback plans to use new capital to expand and accelerate its differentiated pipeline of complex generic and specialty products. Its track record emphasizes execution on difficult products and a focus on regulated markets. Slayback Pharma is a New Jersey–based pharmaceutical research and development company focused on complex generic and specialty products. The company has filed numerous Abbreviated New Drug Applications (ANDAs) and 505(b)(2) applications with the FDA since early 2011 through out-licensing partners. Recent product efforts include Propofol Injectable Emulsion USP 1% and a Generic Zovirax (Acyclovir) Ointment 5%, announced last month. Slayback prioritizes bringing first generics to market and, over the past five years, developed two complex sterile products that became rare sole First-to-File ANDAs with Paragraph IV certification. The company says it is focused on expanding access to affordable health care. The new financing announced will be used to enhance and accelerate development of its portfolio.

Total raised

$110M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2020